Patent · US Active

FN14 antagonists and therapeutic uses thereof

US9238034B2 · kind B2 · utility

11Cited by

1References

9Claims

0Family size

Assignee

The Translational Genomics Research Institute · US

Inventors

Nhan Tran · Phoenix, US
Nathalie Meurice · Scottsdale, US
Harshil Dhruv · Phoenix, US

Key dates

Filing date	Jul 9, 2014
Grant date	Jan 19, 2016
Priority date	—
Expiry date	Jul 9, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K45/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure is directed to methods of using fibroblast growth factor-inducible 14 (Fn14) antagonists to modulate activity at a TNF-like weak inducer of apoptosis (TWEAK) binding site on a cysteine-rich domain (CRD) of Fn14. The present disclosure also provides pharmaceutical compositions comprising synergistic combinations Fn14 antagonists and chemotherapeutic agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.